| http://www.w3.org/ns/prov#value | - A second product, Somatoprim, is expected to start clinical development for the treatment of diabetic retinopathy in 2006.Established in 1998, DeveloGen has evolved into an integrated drug discovery and development company, focused on treatments for types 1 and 2 diabetes and diabetic complications.Estimates suggest about six percent of the worlds population suffers from diabetes, which can be sub
|
